Kara Burke and Nina Camilli from Dana-Farber Cancer Institute were recognized with the DAISY Award
Dana-Farber Cancer Institute shared a post on LinkedIn:
”Kara Burke, a nurse at Dana-Farber – Longwood Medical Area and Nina Camilli, a staff nurse at Dana-Farber – Chestnut Hill, were recently recognized with the DAISY Award, a quarterly honor given to an extraordinary member of the nursing department.
‘From the moment Kara introduced herself at the initial session, I had good vibes and was confident she knew what she was doing and was focused,’ read one nomination for Burke. ‘Kara exhibited such a positive attitude with a smile on her face as she delineated every aspect of my treatment. Each week, I became more and more impressed with her innate ability to clearly and calmly communicate the important elements of my treatment.’
‘Nina is fun, compassionate, caring, and the kind of person that puts you at ease the moment you sit down for treatment,’ read a nomination for Camilli. ‘She makes you feel like you are her only patient and gives you her undivided attention when she’s with you. She is deserving of this award and embodies everything that a patient needs and wants in a nurse.’
The DAISY Foundation (Diseases Attacking the Immune System) established the award in memory of J. Patrick Barnes, whose parents created the foundation in Patrick’s memory after experiencing firsthand the skills, care, and compassion of nurses.”
Source: Dana-Farber Cancer Institute/LinkedIn
Dana-Farber Cancer Institute, located in Boston, Massachusetts, is a leading institution for cancer treatment and research. It was founded by Sidney Farber on 1947. Currently, the Institute has over 5,000 staff, faculty, and clinicians on board. They manage in excess of 640,000 outpatient visits each year, oversee more than 1,000 hospital discharges annually, and are actively involved in over 1,100 ongoing clinical trials.
As of 2023, Dana-Farber is ranked as the #4 cancer hospital globally. Dana-Farber’s research contributions include the development of Gleevec, a highly successful treatment for chronic myeloid leukemia.
